Aquestive Therapeutics (AQST) Invested Capital (2017 - 2026)

Aquestive Therapeutics has reported Invested Capital for 10 years, with the latest figure at -$1.6 million in Q2 2026.

• On a quarterly basis, Invested Capital rose 95.86% year-over-year to -$1.6 million in Q2 2026; TTM through Jun 2026 was -$1.6 million, a 95.86% increase from a year earlier, with the FY2025 full-year figure at $3.9 million, up 113.94% from the prior year.
• Invested Capital was -$1.6 million for Q2 2026 at Aquestive Therapeutics, down from $24.6 million in the prior quarter.
• The five-year high for Invested Capital was $32.2 million in Q3 2025, with the low at -$79.0 million in Q4 2023.
• Average Invested Capital over 5 years is -$27.5 million, with a median of -$32.6 million recorded in 2024.
• The largest YoY upside for Invested Capital was 8241.27% in 2025 against a maximum downside of 493.61% in 2025.
• Over 5 years, Invested Capital stood at -$66.4 million in 2022, then declined by 18.9% to -$79.0 million in 2023, then surged by 65.01% to -$27.6 million in 2024, then surged by 113.94% to $3.9 million in 2025, then plunged by 140.35% to -$1.6 million in 2026.
• The last three Invested Capital figures came in at -$1.6 million (Q2 2026), $24.6 million (Q1 2026), and $3.9 million (Q4 2025), per Business Quant data.